Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The newly certified kits are designed for early detection and large-scale screening programs
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Subscribe To Our Newsletter & Stay Updated
